Coherus BioSciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 306
- Market Cap
- $160.1M
- Website
- http://www.coherus.com
- Introduction
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered i...
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT06679985
A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06657144
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06457503
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT06389526
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT05757492
- Locations
- 🇺🇸
Renown Institute for Cancer, Reno, Nevada, United States
🇺🇸Gabrail Cancer and Research Center, Canton, Ohio, United States
🇺🇸University of Florida Health Cancer Center, Orlando, Florida, United States
Study of CHS-114 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT05635643
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Stanford Cancer Center, Palo Alto, California, United States
🇺🇸Emory Winship Cancer Institute, Atlanta, Georgia, United States
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 134
- Registration Number
- NCT05359861
- Locations
- 🇺🇸
University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸University of Oklahoma Health Sciences Center - Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸Sarah Cannon Research Institute - Tennessee Oncology, Nashville, Tennessee, United States
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05177770
- Locations
- 🇺🇸
START South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸START Mountain Region, Utah Cancer Specialists, West Valley City, Utah, United States
🇨🇦BC Cancer - The Vancouver Centre, Vancouver, British Columbia, Canada
An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT04662892
- Locations
- 🇺🇸
Carolina Blood and Cancer Care, PA, Rock Hill, South Carolina, United States
🇺🇸Coastal Cancer Center, Myrtle Beach, South Carolina, United States
🇺🇸Southern Oncology Specialists, Charlotte, North Carolina, United States
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT04374877
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Southern California (USC) - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States